Physician profile
Caroline Everett
NPI 1831787662
$441.55
in general payments reported to CMS, 2019-2025
11 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $78.23 · 2023: $111 · 2024: $41.32 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $102.32 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $69.92 | 2021-2024 | Fasenra |
| E.R. Squibb & Sons, L.L.C. | $48.72 | 2021-2022 | |
| Bioxcel Therapeutics, INC. | $40.68 | 2023 | Igalmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.74 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.33 | 2021 | |
| Inspire Medical Systems, INC. | $27.98 | 2025 | Inspire |
| Pfizer INC. | $27.88 | 2022 | |
| Boston Scientific Corporation | $22.80 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $18.73 | 2025 | |
| Merck Sharp & Dohme LLC | $18.45 | 2025 | Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.